Anaplastic Astrocytoma Treatment Market - Global Outlook and Forecast 2021-2027

April 2021 | 94 pages | ID: AAC103F96079EN
Market Monitor Global

Abstracts

This report contains market size and forecasts of Anaplastic Astrocytoma Treatment in Global, including the following market information:

Global Anaplastic Astrocytoma Treatment Market Revenue, 2016-2021, 2022-2027, ($ millions)

Global top five companies in 2020 (%)

The global Anaplastic Astrocytoma Treatment market was valued at xx million in 2020 and is projected to reach US$ xx million by 2027, at a CAGR of xx% during the forecast period.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Anaplastic Astrocytoma Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Anaplastic Astrocytoma Treatment Market, By Type, 2016-2021, 2022-2027 ($ millions)

Global Anaplastic Astrocytoma Treatment Market Segment Percentages, By Type, 2020 (%)

• Surgery
• Radiation
• Chemotherapy

China Anaplastic Astrocytoma Treatment Market, By Application, 2016-2021, 2022-2027 ($ millions)

China Anaplastic Astrocytoma Treatment Market Segment Percentages, By Application, 2020 (%)

• Pre-Registration Phase
• Clinical Trail Phase

Global Anaplastic Astrocytoma Treatment Market, By Region and Country, 2016-2021, 2022-2027 ($ Millions)

Global Anaplastic Astrocytoma Treatment Market Segment Percentages, By Region and Country, 2020 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Total Anaplastic Astrocytoma Treatment Market Competitors Revenues in Global, by Players 2016-2021 (Estimated), ($ millions)

Total Anaplastic Astrocytoma Treatment Market Competitors Revenues Share in Global, by Players 2020 (%)

Further, the report presents profiles of competitors in the market, including the following:

• Axelar
• Pfizer
• Amgen
• Genentech
• Isarna Therapeutics GmbH
• Novartis
• Peregrine Pharmaceuticals
• EirGen Pharma
• Boehringer Ingelheim
• Celldex Therapeutics

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

1.1 Anaplastic Astrocytoma Treatment Market Definition
1.2 Market Segments
  1.2.1 Market by Type
  1.2.2 Market by Application
1.3 Global Anaplastic Astrocytoma Treatment Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
  1.5.1 Research Methodology
  1.5.2 Research Process
  1.5.3 Base Year
  1.5.4 Report Assumptions & Caveats

2 GLOBAL ANAPLASTIC ASTROCYTOMA TREATMENT OVERALL MARKET SIZE

2.1 Global Anaplastic Astrocytoma Treatment Market Size: 2021 VS 2027
2.2 Global Anaplastic Astrocytoma Treatment Market Size, Prospects & Forecasts: 2016-2027
2.3 Key Market Trends, Opportunity, Drivers and Restraints
  2.3.1 Market Opportunities & Trends
  2.3.2 Market Drivers
  2.3.3 Market Restraints

3 COMPANY LANDSCAPE

3.1 Top Anaplastic Astrocytoma Treatment Players in Global Market
3.2 Top Global Anaplastic Astrocytoma Treatment Companies Ranked by Revenue
3.3 Global Anaplastic Astrocytoma Treatment Revenue by Companies
3.4 Top 3 and Top 5 Anaplastic Astrocytoma Treatment Companies in Global Market, by Revenue in 2020
3.5 Global Companies Anaplastic Astrocytoma Treatment Product Type
3.6 Tier 1, Tier 2 and Tier 3 Anaplastic Astrocytoma Treatment Players in Global Market
  3.6.1 List of Global Tier 1 Anaplastic Astrocytoma Treatment Companies
  3.6.2 List of Global Tier 2 and Tier 3 Anaplastic Astrocytoma Treatment Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview
  4.1.1 By Type - Global Anaplastic Astrocytoma Treatment Market Size Markets, 2021 & 2027
  4.1.2 Surgery
  4.1.3 Radiation
  4.1.4 Chemotherapy
4.2 By Type - Global Anaplastic Astrocytoma Treatment Revenue & Forecasts
  4.2.1 By Type - Global Anaplastic Astrocytoma Treatment Revenue, 2016-2021
  4.2.2 By Type - Global Anaplastic Astrocytoma Treatment Revenue, 2022-2027
  4.2.3 By Type - Global Anaplastic Astrocytoma Treatment Revenue Market Share, 2016-2027

5 SIGHTS BY APPLICATION

5.1 Overview
  5.1.1 By Application - Global Anaplastic Astrocytoma Treatment Market Size, 2021 & 2027
  5.1.2 Pre-Registration Phase
  5.1.3 Clinical Trail Phase
5.2 By Application - Global Anaplastic Astrocytoma Treatment Revenue & Forecasts
  5.2.1 By Application - Global Anaplastic Astrocytoma Treatment Revenue, 2016-2021
  5.2.2 By Application - Global Anaplastic Astrocytoma Treatment Revenue, 2022-2027
  5.2.3 By Application - Global Anaplastic Astrocytoma Treatment Revenue Market Share, 2016-2027

6 SIGHTS BY REGION

6.1 By Region - Global Anaplastic Astrocytoma Treatment Market Size, 2021 & 2027
6.2 By Region - Global Anaplastic Astrocytoma Treatment Revenue & Forecasts
  6.2.1 By Region - Global Anaplastic Astrocytoma Treatment Revenue, 2016-2021
  6.2.2 By Region - Global Anaplastic Astrocytoma Treatment Revenue, 2022-2027
  6.2.3 By Region - Global Anaplastic Astrocytoma Treatment Revenue Market Share, 2016-2027
6.3 North America
  6.3.1 By Country - North America Anaplastic Astrocytoma Treatment Revenue, 2016-2027
  6.3.2 US Anaplastic Astrocytoma Treatment Market Size, 2016-2027
  6.3.3 Canada Anaplastic Astrocytoma Treatment Market Size, 2016-2027
  6.3.4 Mexico Anaplastic Astrocytoma Treatment Market Size, 2016-2027
6.4 Europe
  6.4.1 By Country - Europe Anaplastic Astrocytoma Treatment Revenue, 2016-2027
  6.4.2 Germany Anaplastic Astrocytoma Treatment Market Size, 2016-2027
  6.4.3 France Anaplastic Astrocytoma Treatment Market Size, 2016-2027
  6.4.4 U.K. Anaplastic Astrocytoma Treatment Market Size, 2016-2027
  6.4.5 Italy Anaplastic Astrocytoma Treatment Market Size, 2016-2027
  6.4.6 Russia Anaplastic Astrocytoma Treatment Market Size, 2016-2027
  6.4.7 Nordic Countries Anaplastic Astrocytoma Treatment Market Size, 2016-2027
  6.4.8 Benelux Anaplastic Astrocytoma Treatment Market Size, 2016-2027
6.5 Asia
  6.5.1 By Region - Asia Anaplastic Astrocytoma Treatment Revenue, 2016-2027
  6.5.2 China Anaplastic Astrocytoma Treatment Market Size, 2016-2027
  6.5.3 Japan Anaplastic Astrocytoma Treatment Market Size, 2016-2027
  6.5.4 South Korea Anaplastic Astrocytoma Treatment Market Size, 2016-2027
  6.5.5 Southeast Asia Anaplastic Astrocytoma Treatment Market Size, 2016-2027
  6.5.6 India Anaplastic Astrocytoma Treatment Market Size, 2016-2027
6.6 South America
  6.6.1 By Country - South America Anaplastic Astrocytoma Treatment Revenue, 2016-2027
  6.6.2 Brazil Anaplastic Astrocytoma Treatment Market Size, 2016-2027
  6.6.3 Argentina Anaplastic Astrocytoma Treatment Market Size, 2016-2027
6.7 Middle East & Africa
  6.7.1 By Country - Middle East & Africa Anaplastic Astrocytoma Treatment Revenue, 2016-2027
  6.7.2 Turkey Anaplastic Astrocytoma Treatment Market Size, 2016-2027
  6.7.3 Israel Anaplastic Astrocytoma Treatment Market Size, 2016-2027
  6.7.4 Saudi Arabia Anaplastic Astrocytoma Treatment Market Size, 2016-2027
  6.7.5 UAE Anaplastic Astrocytoma Treatment Market Size, 2016-2027

7 PLAYERS PROFILES

7.1 Axelar
  7.1.1 Axelar Corporate Summary
  7.1.2 Axelar Business Overview
  7.1.3 Axelar Anaplastic Astrocytoma Treatment Major Product Offerings
  7.1.4 Axelar Anaplastic Astrocytoma Treatment Revenue in Global (2016-2021)
  7.1.5 Axelar Key News
7.2 Pfizer
  7.2.1 Pfizer Corporate Summary
  7.2.2 Pfizer Business Overview
  7.2.3 Pfizer Anaplastic Astrocytoma Treatment Major Product Offerings
  7.2.4 Pfizer Anaplastic Astrocytoma Treatment Revenue in Global (2016-2021)
  7.2.5 Pfizer Key News
7.3 Amgen
  7.3.1 Amgen Corporate Summary
  7.3.2 Amgen Business Overview
  7.3.3 Amgen Anaplastic Astrocytoma Treatment Major Product Offerings
  7.3.4 Amgen Anaplastic Astrocytoma Treatment Revenue in Global (2016-2021)
  7.3.5 Amgen Key News
7.4 Genentech
  7.4.1 Genentech Corporate Summary
  7.4.2 Genentech Business Overview
  7.4.3 Genentech Anaplastic Astrocytoma Treatment Major Product Offerings
  7.4.4 Genentech Anaplastic Astrocytoma Treatment Revenue in Global (2016-2021)
  7.4.5 Genentech Key News
7.5 Isarna Therapeutics GmbH
  7.5.1 Isarna Therapeutics GmbH Corporate Summary
  7.5.2 Isarna Therapeutics GmbH Business Overview
  7.5.3 Isarna Therapeutics GmbH Anaplastic Astrocytoma Treatment Major Product Offerings
  7.5.4 Isarna Therapeutics GmbH Anaplastic Astrocytoma Treatment Revenue in Global (2016-2021)
  7.5.5 Isarna Therapeutics GmbH Key News
7.6 Novartis
  7.6.1 Novartis Corporate Summary
  7.6.2 Novartis Business Overview
  7.6.3 Novartis Anaplastic Astrocytoma Treatment Major Product Offerings
  7.6.4 Novartis Anaplastic Astrocytoma Treatment Revenue in Global (2016-2021)
  7.6.5 Novartis Key News
7.7 Peregrine Pharmaceuticals
  7.7.1 Peregrine Pharmaceuticals Corporate Summary
  7.7.2 Peregrine Pharmaceuticals Business Overview
  7.7.3 Peregrine Pharmaceuticals Anaplastic Astrocytoma Treatment Major Product Offerings
  7.4.4 Peregrine Pharmaceuticals Anaplastic Astrocytoma Treatment Revenue in Global (2016-2021)
  7.7.5 Peregrine Pharmaceuticals Key News
7.8 EirGen Pharma
  7.8.1 EirGen Pharma Corporate Summary
  7.8.2 EirGen Pharma Business Overview
  7.8.3 EirGen Pharma Anaplastic Astrocytoma Treatment Major Product Offerings
  7.8.4 EirGen Pharma Anaplastic Astrocytoma Treatment Revenue in Global (2016-2021)
  7.8.5 EirGen Pharma Key News
7.9 Boehringer Ingelheim
  7.9.1 Boehringer Ingelheim Corporate Summary
  7.9.2 Boehringer Ingelheim Business Overview
  7.9.3 Boehringer Ingelheim Anaplastic Astrocytoma Treatment Major Product Offerings
  7.9.4 Boehringer Ingelheim Anaplastic Astrocytoma Treatment Revenue in Global (2016-2021)
  7.9.5 Boehringer Ingelheim Key News
7.10 Celldex Therapeutics
  7.10.1 Celldex Therapeutics Corporate Summary
  7.10.2 Celldex Therapeutics Business Overview
  7.10.3 Celldex Therapeutics Anaplastic Astrocytoma Treatment Major Product Offerings
  7.10.4 Celldex Therapeutics Anaplastic Astrocytoma Treatment Revenue in Global (2016-2021)
  7.10.5 Celldex Therapeutics Key News

8 CONCLUSION

9 APPENDIX

9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Anaplastic Astrocytoma Treatment Market Opportunities & Trends in Global Market
Table 2. Anaplastic Astrocytoma Treatment Market Drivers in Global Market
Table 3. Anaplastic Astrocytoma Treatment Market Restraints in Global Market
Table 4. Key Players of Anaplastic Astrocytoma Treatment in Global Market
Table 5. Top Anaplastic Astrocytoma Treatment Players in Global Market, Ranking by Revenue (2019)
Table 6. Global Anaplastic Astrocytoma Treatment Revenue by Companies, (US$, Mn), 2016-2021
Table 7. Global Anaplastic Astrocytoma Treatment Revenue Share by Companies, 2016-2021
Table 8. Global Companies Anaplastic Astrocytoma Treatment Product Type
Table 9. List of Global Tier 1 Anaplastic Astrocytoma Treatment Companies, Revenue (US$, Mn) in 2020 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Anaplastic Astrocytoma Treatment Companies, Revenue (US$, Mn) in 2020 and Market Share
Table 11. By Type – Global Anaplastic Astrocytoma Treatment Revenue, (US$, Mn), 2021 VS 2027
Table 12. By Type - Anaplastic Astrocytoma Treatment Revenue in Global (US$, Mn), 2016-2021
Table 13. By Type - Anaplastic Astrocytoma Treatment Revenue in Global (US$, Mn), 2022-2027
Table 14. By Application – Global Anaplastic Astrocytoma Treatment Revenue, (US$, Mn), 2021 VS 2027
Table 15. By Application - Anaplastic Astrocytoma Treatment Revenue in Global (US$, Mn), 2016-2021
Table 16. By Application - Anaplastic Astrocytoma Treatment Revenue in Global (US$, Mn), 2022-2027
Table 17. By Region – Global Anaplastic Astrocytoma Treatment Revenue, (US$, Mn), 2021 VS 2027
Table 18. By Region - Global Anaplastic Astrocytoma Treatment Revenue (US$, Mn), 2016-2021
Table 19. By Region - Global Anaplastic Astrocytoma Treatment Revenue (US$, Mn), 2022-2027
Table 20. By Country - North America Anaplastic Astrocytoma Treatment Revenue, (US$, Mn), 2016-2021
Table 21. By Country - North America Anaplastic Astrocytoma Treatment Revenue, (US$, Mn), 2022-2027
Table 22. By Country - Europe Anaplastic Astrocytoma Treatment Revenue, (US$, Mn), 2016-2021
Table 23. By Country - Europe Anaplastic Astrocytoma Treatment Revenue, (US$, Mn), 2022-2027
Table 24. By Region - Asia Anaplastic Astrocytoma Treatment Revenue, (US$, Mn), 2016-2021
Table 25. By Region - Asia Anaplastic Astrocytoma Treatment Revenue, (US$, Mn), 2022-2027
Table 26. By Country - South America Anaplastic Astrocytoma Treatment Revenue, (US$, Mn), 2016-2021
Table 27. By Country - South America Anaplastic Astrocytoma Treatment Revenue, (US$, Mn), 2022-2027
Table 28. By Country - Middle East & Africa Anaplastic Astrocytoma Treatment Revenue, (US$, Mn), 2016-2021
Table 29. By Country - Middle East & Africa Anaplastic Astrocytoma Treatment Revenue, (US$, Mn), 2022-2027
Table 30. Axelar Corporate Summary
Table 31. Axelar Anaplastic Astrocytoma Treatment Product Offerings
Table 32. Axelar Anaplastic Astrocytoma Treatment Revenue (US$, Mn), (2016-2021)
Table 33. Pfizer Corporate Summary
Table 34. Pfizer Anaplastic Astrocytoma Treatment Product Offerings
Table 35. Pfizer Anaplastic Astrocytoma Treatment Revenue (US$, Mn), (2016-2021)
Table 36. Amgen Corporate Summary
Table 37. Amgen Anaplastic Astrocytoma Treatment Product Offerings
Table 38. Amgen Anaplastic Astrocytoma Treatment Revenue (US$, Mn), (2016-2021)
Table 39. Genentech Corporate Summary
Table 40. Genentech Anaplastic Astrocytoma Treatment Product Offerings
Table 41. Genentech Anaplastic Astrocytoma Treatment Revenue (US$, Mn), (2016-2021)
Table 42. Isarna Therapeutics GmbH Corporate Summary
Table 43. Isarna Therapeutics GmbH Anaplastic Astrocytoma Treatment Product Offerings
Table 44. Isarna Therapeutics GmbH Anaplastic Astrocytoma Treatment Revenue (US$, Mn), (2016-2021)
Table 45. Novartis Corporate Summary
Table 46. Novartis Anaplastic Astrocytoma Treatment Product Offerings
Table 47. Novartis Anaplastic Astrocytoma Treatment Revenue (US$, Mn), (2016-2021)
Table 48. Peregrine Pharmaceuticals Corporate Summary
Table 49. Peregrine Pharmaceuticals Anaplastic Astrocytoma Treatment Product Offerings
Table 50. Peregrine Pharmaceuticals Anaplastic Astrocytoma Treatment Revenue (US$, Mn), (2016-2021)
Table 51. EirGen Pharma Corporate Summary
Table 52. EirGen Pharma Anaplastic Astrocytoma Treatment Product Offerings
Table 53. EirGen Pharma Anaplastic Astrocytoma Treatment Revenue (US$, Mn), (2016-2021)
Table 54. Boehringer Ingelheim Corporate Summary
Table 55. Boehringer Ingelheim Anaplastic Astrocytoma Treatment Product Offerings
Table 56. Boehringer Ingelheim Anaplastic Astrocytoma Treatment Revenue (US$, Mn), (2016-2021)
Table 57. Celldex Therapeutics Corporate Summary
Table 58. Celldex Therapeutics Anaplastic Astrocytoma Treatment Product Offerings
Table 59. Celldex Therapeutics Anaplastic Astrocytoma Treatment Revenue (US$, Mn), (2016-2021)

List Of Figures

LIST OF FIGURES

Figure 1. Anaplastic Astrocytoma Treatment Segment by Type
Figure 2. Anaplastic Astrocytoma Treatment Segment by Application
Figure 3. Global Anaplastic Astrocytoma Treatment Market Overview: 2020
Figure 4. Key Caveats
Figure 5. Global Anaplastic Astrocytoma Treatment Market Size: 2021 VS 2027 (US$, Mn)
Figure 6. Global Anaplastic Astrocytoma Treatment Revenue, 2016-2027 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Anaplastic Astrocytoma Treatment Revenue in 2020
Figure 8. By Type - Global Anaplastic Astrocytoma Treatment Revenue Market Share, 2016-2027
Figure 9. By Application - Global Anaplastic Astrocytoma Treatment Revenue Market Share, 2016-2027
Figure 10. By Region - Global Anaplastic Astrocytoma Treatment Revenue Market Share, 2016-2027
Figure 11. By Country - North America Anaplastic Astrocytoma Treatment Revenue Market Share, 2016-2027
Figure 12. US Anaplastic Astrocytoma Treatment Revenue, (US$, Mn), 2016-2027
Figure 13. Canada Anaplastic Astrocytoma Treatment Revenue, (US$, Mn), 2016-2027
Figure 14. Mexico Anaplastic Astrocytoma Treatment Revenue, (US$, Mn), 2016-2027
Figure 15. By Country - Europe Anaplastic Astrocytoma Treatment Revenue Market Share, 2016-2027
Figure 16. Germany Anaplastic Astrocytoma Treatment Revenue, (US$, Mn), 2016-2027
Figure 17. France Anaplastic Astrocytoma Treatment Revenue, (US$, Mn), 2016-2027
Figure 18. U.K. Anaplastic Astrocytoma Treatment Revenue, (US$, Mn), 2016-2027
Figure 19. Italy Anaplastic Astrocytoma Treatment Revenue, (US$, Mn), 2016-2027
Figure 20. Russia Anaplastic Astrocytoma Treatment Revenue, (US$, Mn), 2016-2027
Figure 21. Nordic Countries Anaplastic Astrocytoma Treatment Revenue, (US$, Mn), 2016-2027
Figure 22. Benelux Anaplastic Astrocytoma Treatment Revenue, (US$, Mn), 2016-2027
Figure 23. By Region - Asia Anaplastic Astrocytoma Treatment Revenue Market Share, 2016-2027
Figure 24. China Anaplastic Astrocytoma Treatment Revenue, (US$, Mn), 2016-2027
Figure 25. Japan Anaplastic Astrocytoma Treatment Revenue, (US$, Mn), 2016-2027
Figure 26. South Korea Anaplastic Astrocytoma Treatment Revenue, (US$, Mn), 2016-2027
Figure 27. Southeast Asia Anaplastic Astrocytoma Treatment Revenue, (US$, Mn), 2016-2027
Figure 28. India Anaplastic Astrocytoma Treatment Revenue, (US$, Mn), 2016-2027
Figure 29. By Country - South America Anaplastic Astrocytoma Treatment Revenue Market Share, 2016-2027
Figure 30. Brazil Anaplastic Astrocytoma Treatment Revenue, (US$, Mn), 2016-2027
Figure 31. Argentina Anaplastic Astrocytoma Treatment Revenue, (US$, Mn), 2016-2027
Figure 32. By Country - Middle East & Africa Anaplastic Astrocytoma Treatment Revenue Market Share, 2016-2027
Figure 33. Turkey Anaplastic Astrocytoma Treatment Revenue, (US$, Mn), 2016-2027
Figure 34. Israel Anaplastic Astrocytoma Treatment Revenue, (US$, Mn), 2016-2027
Figure 35. Saudi Arabia Anaplastic Astrocytoma Treatment Revenue, (US$, Mn), 2016-2027
Figure 36. UAE Anaplastic Astrocytoma Treatment Revenue, (US$, Mn), 2016-2027
Figure 37. Axelar Anaplastic Astrocytoma Treatment Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 38. Pfizer Anaplastic Astrocytoma Treatment Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 39. Amgen Anaplastic Astrocytoma Treatment Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 40. Genentech Anaplastic Astrocytoma Treatment Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 41. Isarna Therapeutics GmbH Anaplastic Astrocytoma Treatment Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 42. Novartis Anaplastic Astrocytoma Treatment Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 43. Peregrine Pharmaceuticals Anaplastic Astrocytoma Treatment Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 44. EirGen Pharma Anaplastic Astrocytoma Treatment Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 45. Boehringer Ingelheim Anaplastic Astrocytoma Treatment Revenue Year Over Year Growth (US$, Mn) & (2016-2021)